BCL2 and cancer: In sum, we demonstrated for the first time that the compound C2.01 inhibits specific La:RNA interactions in cells and sensitizes cancer cells for cisplatin treatment, likley by reducing the binding of La to Bcl2 mRNA, leading to reduced expression of anti-apoptotic factor Bcl2.